Analyst Price Targets — PCVX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 25, 2026 7:27 pm | Tom Shrader | BTIG | $89.00 | $63.04 | StreetInsider | Vaxcyte (PCVX) PT Raised to $89 at BTIG |
| November 19, 2025 10:23 am | David Risinger | Leerink Partners | $77.00 | $49.53 | StreetInsider | Vaxcyte (PCVX) PT Raised to $77 at Leerink Partners |
| November 6, 2024 11:13 am | Roger Song | Jefferies | $146.00 | $106.74 | StreetInsider | Vaxcyte (PCVX) PT Raised to $146 at Jefferies |
| November 6, 2024 10:59 am | David Risinger | Leerink Partners | $135.00 | $106.74 | StreetInsider | Leerink Partners Reiterates Outperform Rating on Vaxcyte (PCVX) |
| September 10, 2024 6:46 am | Salim Syed | Mizuho Securities | $163.00 | $115.28 | TheFly | Vaxcyte price target raised to $163 from $113 at Mizuho |
| September 4, 2024 6:34 am | Jason Gerberry | Bank of America Securities | $140.00 | $110.15 | TheFly | Vaxcyte price target raised to $140 from $101 at BofA |
| September 3, 2024 2:34 pm | David Risinger | Leerink Partners | $153.00 | $112.04 | TheFly | Vaxcyte price target raised to $153 at Leerink after VAX-31 'home run' |
| September 3, 2024 11:48 am | Tom Shrader | BTIG | $160.00 | $110.15 | StreetInsider | Vaxcyte (PCVX) PT Raised to $160 at BTIG |
| September 3, 2024 9:33 am | Roger Song | Jefferies | $129.00 | $111.13 | StreetInsider | Vaxcyte (PCVX) PT Raised to $129 at Jefferies |
| September 3, 2024 8:25 am | Salim Syed | Mizuho Securities | $113.00 | $111.09 | StreetInsider | Mizuho Reiterates Outperform Rating on Vaxcyte (PCVX) |
Latest News for PCVX
SAN CARLOS, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in and host one-on-one meetings at the following investor conferences:
First-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus
Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Vaxcyte is evolving from a single-product biotech into a commercial vaccine platform with advanced manufacturing and regulatory alignment. VAX-31, a 31-valent pneumococcal conjugate vaccine, targets broader serotype coverage than competitors and is in pivotal Phase 3 adult and Phase 2 infant trials. PCVX boasts strong financials, with over $2.4B in cash and a completed manufacturing facility, enabling concurrent…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PCVX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.